October 11, 2015

FDA Approves Endologix's AFX2 Bifurcated Endograft System

October 12, 2015—Endologix, Inc. announced that it has received US Food and Drug Administration approval for the AFX2 bifurcated endograft system for the treatment of abdominal aortic aneurysms. Endologix will introduce the AFX2 at the 2015 VEITH symposium on November 17–21, 2015 in New York, New York, which will be followed by a commercial launch in the United States that is expected to begin in the first quarter of 2016.

According to Endologix, the AFX2 device reduces procedure steps for the delivery and deployment of the bifurcated endograft. The new device also facilitates percutaneous EVAR by providing low-profile contralateral access through a 7F introducer. The AFX2 incorporates Endologix’s ActiveSeal technology, DuraPly expanded polytetrafluoroethylene graft material, and the Vela proximal endograft.

Subscribe to our weekly newsletter.

Stay informed on the week's top stories including literature summaries, device approvals, guideline changes, and more. Plus, get our latest issues & supplements delivered to your inbox each month.

October 11, 2015

FDA Approves Endologix's AFX2 Bifurcated Endograft System

Current Issue

Keep In Touch